Magistral drug preparation offers a model to circumvent many of the technological, regulatory and financial challenges that prevent provision of the right drug at the right time to the right patient.
Change history
05 June 2017
In the version of this article initially published, the line “Editor’s note: This article has been peer-reviewed.” was omitted. The error has been corrected in the HTML and PDF versions of the article.
References
Olfson, M. & Marcus, S.C. Health Aff. (Millwood) 32, 1116–1125 (2013).
Le Tourneau, C. et al. Lancet Oncol. 16, 1324–1334 (2015).
Pirmohamed, M. et al. Br. Med. J. 329, 15–19 (2004).
Jameson, J. & Longo, D.L. N. Engl. J. Med. 372, 2229–2234 (2015).
Faulkner, E. et al. Value Health 15, 1162–1171 (2012).
Carrera, P.M. & Ormond, M. Maturitas 82, 94–99 (2015).
Cohen, J.P. Nat. Biotechnol. 29, 751–756 (2012).
de Bono, J.S. & Ashworth, A. Nature 467, 543–549 (2010).
Damkier, P. Int. J. Clin. Pharm. 37, 669–670 (2015).
Collins, F.S. & Varmus, H. N. Engl. J. Med. 372, 793–795 (2015).
Okie, S. N. Engl. J. Med. 361, 737–740 (2009).
Avorn, J. N. Engl. J. Med. 367, 193–197 (2012).
Frueh, F.W. Value Health 16 Suppl, S27–S31 (2013).
Fleck, L.M. Urol. Oncol. 32, 202–206 (2014).
Kalia, M. Metabolism 62 Suppl 1, S1–14 (2013).
Moors, E.H., Cohen, A.F. & Schellekens, H. Drug Discov. Today 19, 1711–1720 (2014).
European Public Assessment Report Glybera (EMA Website)
Aronson, N. Ann. NY Acad. Sci. 1346, 81–89 (2015).
Abernethy, A. et al. Clin. Cancer Res. 20, 1081–1086 (2014).
Steger, K. et al. J. Biomol. Screen. 20, 545–551 (2015).
Ge, X. et al. J. Am. Chem. Soc. 127, 11228–11229 (2005).
Topol, E.J. N. Engl. J. Med. 351, 1707–1709 (2004).
Minghetti, P., Pantano, D., Gennari, C.G. & Casiraghi, A. Health Policy 117, 328–333 (2014).
Qureshi, N., Wesolowicz, L., Stievater, T. & Lin, A.T. J. Manag. Care Spec. Pharm. 20, 1183–1191 (2014).
McKoy, J.M. et al. Transfusion 48, 1754–1762 (2008).
Kooijman, M., van Meer, P.J., Moors, E.H. & Schellekens, H. Expert Opin. Drug Saf. 11, 797–801 (2012).
van Meer, P.J. et al. MAbs 5, 810–816 (2013).
Schneider, C.K. & Kalinke, U. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 50, 1213–1220 (2007).
Patten, P.A. & Schellekens, H. Dev. Biol. 112, 81–97 (2003).
Bach, P.B., Conti, R.M., Muller, R.J., Schnorr, G.C. & Saltz, L.B. Br. Med. J. 352, i788 (2016).
Ciriminna, R. et al. Nanoscale 6, 6293–6300 (2014).
Gising, J., Odell, L.R. & Larhed, M. Org. Biomol. Chem. 10, 2713–2729 (2012).
Szymkuć, S. et al. Angew. Chem. Int. Edn Engl. 55, 5904–5937 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Schellekens, H., Aldosari, M., Talsma, H. et al. Making individualized drugs a reality. Nat Biotechnol 35, 507–513 (2017). https://doi.org/10.1038/nbt.3888
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3888
- Springer Nature America, Inc.
This article is cited by
-
Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases
Orphanet Journal of Rare Diseases (2022)
-
Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics
Pharmaceutical Research (2021)
-
Versatile biomanufacturing through stimulus-responsive cell–material feedback
Nature Chemical Biology (2019)
-
Magistral drug production in Colombia and other middle-income countries
Nature Biotechnology (2019)
-
A perspective on multi‐target drug discovery and design for complex diseases
Clinical and Translational Medicine (2018)